NFE2L2 and cancer: To investigate the predictive efficacy of NFE2L2 MU for ICI treatment in pan-cancer, we evaluated the association between NFE2L2 MU and clinical outcomes in multiple types tumors of a pooled cohort (n = 2611) composed of DFCI, MSK, MSK1661, OAK, Pender, POPLAR and PUCH cohorts.